House Sends ALS Research Extension Bill to President
The legislation secures funding for ALS research and establishes new clinical trial pathways through 2031.
Updated on Oct. 29, 2026 in Alzheimer’s
Live Poll
Should the federal government prioritize long-term funding for research into fatal diseases?
The U.S. House of Representatives has passed the Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026, officially sending the bill to President Donald Trump. The legislation aims to sustain research efforts for a disease that currently maintains a 100% fatality rate.
Why it matters
This bill ensures the continuation of vital research programs and grant initiatives that began in 2021. By codifying FDA mandates for rare neurodegenerative diseases, the act seeks to bridge the gap between experimental treatments and patient access.
The legislation, filed as U.S. House Bill 8205, requires an FDA action plan for rare neurodegenerative diseases within 18 months. An implementation report for the plan is mandated within five years to track program progress.
The players
President Donald Trump
He is the current President of the United States who now holds the authority to sign or veto the legislation.
U.S. House of Representatives
This is the lower chamber of the United States Congress responsible for passing federal legislation.
Food and Drug Administration
This is a federal agency responsible for protecting public health by ensuring the safety and efficacy of medical products.
National Institutes of Health
This is the primary agency of the United States government responsible for biomedical and public health research.
The details
The act provides expanded pathways for individuals with ALS to enroll in clinical trials while fostering partnerships between the National Institutes of Health and the FDA. ALS has remained a focus of medical scrutiny since Lou Gehrig was famously diagnosed with the condition in 1939.
Timeline
1939: Lou Gehrig was diagnosed with ALS.
2021: ACT for ALS programs began.
Nov. 6, 2026: Deadline for President Trump to act on the bill.
Nov. 7, 2026: Date bill becomes law if president takes no action.
2031: Expiration of extended funding for ALS initiatives.
Health Landscape
This legislation builds upon the foundation established by the ACT for ALS programs to continue addressing the needs of patients with neurodegenerative conditions. It reflects a shift toward institutionalizing pathways for rare disease research that were previously experimental.
Patients with ALS may gain more consistent access to clinical trial opportunities as the FDA develops new action plans for rare diseases. These programs aim to provide life-extending research pathways that were previously less accessible.
The takeaway
This legislation provides a critical long-term roadmap for researchers aiming to treat a disease with a 100% fatality rate. Stakeholders should monitor for the FDA action plan release, which will dictate the specific mechanisms for future trial enrollments.
Further reading
For more information on neurodegenerative disease support, visit the Alzheimer’s resource page.
Source note: This article includes information reported by Huron Daily Tribune.
Live Poll
Should the federal government prioritize long-term funding for research into fatal diseases?
